A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
← catalyst calendarNCT05667142 · readout ≤ 253 d
Sponsored by Xenon Pharmaceuticals Inc. (industry) · XENE — their whole pipeline →. With Worldwide Clinical Trials.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
160estimated
Sites
138
Countries
Argentina, Australia, Austria +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-14 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Generalized Tonic-Clonic Seizures
Interventions
- Drug: XEN1101 — also filed as Azetukalner
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFMedian percent change (MPC) in monthly (28 days) PGTCS frequency
measured Baseline through DBP (Week 12)
Permalink · XENE's whole pipeline · Catalyst calendar · Every registered study · What changed